Company profile for Keros Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Keros focuses on the role of members of the TGF-β family of proteins in the development of blood cells, muscle and bone. Aged and damaged cells are routinely replaced by new cells in normally functioning organs. These new cells are derived from stem cells that have the ability to differentiate into cells with specialized function when appropriate signals are provided to maintain the homeostatic state of the tissue. Members of...
Keros focuses on the role of members of the TGF-β family of proteins in the development of blood cells, muscle and bone. Aged and damaged cells are routinely replaced by new cells in normally functioning organs. These new cells are derived from stem cells that have the ability to differentiate into cells with specialized function when appropriate signals are provided to maintain the homeostatic state of the tissue. Members of the TGF-β family of proteins, including activins and bone morphogenetic proteins, provide the necessary signals for this process of self-renewal and repair.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Keros Therapeutics 99 Hayden Avenue Suite 120, Building E Lexington, MA 02421
Telephone
Telephone
+1 (617) 314-6297
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/20/3192367/0/en/Keros-Therapeutics-Announces-Final-Results-of-Tender-Offer.html

GLOBENEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/11/19/3190740/0/en/Keros-Therapeutics-Announces-Preliminary-Results-of-Tender-Offer.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181905/0/en/Keros-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/20/3169169/0/en/Keros-Therapeutics-Commences-Issuer-Tender-Offer-to-Repurchase-up-to-194-4-Million-Shares.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/10/15/3166903/0/en/Keros-Therapeutics-Announces-Plan-for-Return-of-375-Million-in-Excess-Capital.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/09/08/3146059/0/en/Keros-Therapeutics-Presents-Additional-Clinical-Data-from-its-KER-065-Program-at-the-American-Society-of-Bone-and-Mineral-Research-2025-Annual-Meeting.html

GLOBENEWSWIRE
08 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty